Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.M400302-JLR200 on October 1, 2004

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M400302-JLR200v1
45/12/2354    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meaney, S.
Right arrow Articles by Thomassen, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meaney, S.
Right arrow Articles by Thomassen, M. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 45, 2354-2360, December 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

Serum cholestenoic acid as a potential marker of pulmonary cholesterol homeostasis

: increased levels in patients with pulmonary alveolar proteinosis

Steve Meaney1,*, Tracey L. Bonfield{dagger}, Magnus Hansson*, Amir Babiker*, Mani S. Kavuru{dagger} and Mary Jane Thomassen{dagger}

* Division of Clinical Chemistry, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
{dagger} Cytokine Biology Laboratory, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, OH

Published, JLR Papers in Press, October 1, 2004. DOI 10.1194/jlr.M400302-JLR200

1 To whom correspondence should be addressed. e-mail: steve.meaney{at}labmed.ki.se


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The conversion of cholesterol into the more polar metabolites 27-hydroxycholesterol (27-OH) and cholestenoic acid by the cytochrome P450 sterol 27-hydroxylase is a cholesterol-removal mechanism used by almost all cells. Most of the cholestenoic acid present in the circulation originates from the lung, and it has been suggested that sterol 27-hydroxylase is of particular importance for cholesterol homeostasis in this organ. As an example of pulmonary cholesterol accumulation, a known disorder of surfactant homeostasis, pulmonary alveolar proteinosis (PAP), was studied. Analysis of bronchoalveolar lavage fluid from PAP patients revealed a significant accumulation of the cholesterol metabolites cholestenoic acid and 27-OH. This pattern was recapitulated in serum, with a significant increase in the levels of both cholestenoic acid (P = 0.003) and 27-OH (P = 0.017) in PAP patients compared with healthy controls. Analysis of PAP alveolar macrophages did not reveal a significant change in mRNA expression levels of either sterol 27-hydroxylase or the cholesterol-esterifying enzyme acyl-CoA:cholesterol acyltransferase-1.

These results are consistent with the contention that substrate availability, rather than enzyme expression, is the key factor in regulating the production of cholestenoic acid by the lung and that serum cholestenoic acid may be a marker of pulmonary cholesterol homeostasis.

Supplementary key words pulmonary surfactant • cytochrome P450 sterol 27-hydroxylase • 27-hydroxycholesterol • oxysterol


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The conversion of cholesterol into the more polar metabolites 27-hydroxycholesterol (27-OH) and 3ß-hydroxy-5-cholestenoic acid (cholestenoic acid) is a widespread occurrence in vertebrate tissues. In addition to having an essential role in bile acid biosynthesis, this conversion is also believed to be an antiatherogenic mechanism (1). This transformation is mediated by the activity of the cytochrome P450 sterol 27-hydroxylase (CYP27A1), which, unusual for a cytochrome P450, is able to further hydroxylate 27-OH at the C-27 position, leading to the production of the carboxylic acid cholestenoic acid (2). Cells of monocytic lineage are highly active in this reaction, with alveolar macrophages being the most active cell type tested to date (3). It has been demonstrated that the majority of cholestenoic acid present in the circulation is derived from the lung (4), suggesting that CYP27A1-mediated reverse cholesterol transport is important in lung cholesterol homeostasis.

Cholesterol is the most abundant neutral lipid of pulmonary surfactant, constituting up to 90% of the neutral lipid material (5). At least 80% of the cholesterol present in the lung, and virtually all that in surfactant, is derived from circulating lipoproteins (6), with very low density lipoprotein believed to be the major vehicle for this delivery. Type II pneumocytes are believed to be responsible for the majority of uptake, packaging, and secretion of the surfactant components (7). Moreover, surfactant lipids are efficiently recycled by the type II pneumocytes, with up to half of the material taken up resecreted into the surfactant compartment (8). The remaining material is believed to be catabolized by alveolar macrophages and eliminated from the lung (8). However, the exact mechanisms by which surfactant cholesterol is removed are poorly understood.

Pulmonary alveolar proteinosis (PAP), first described in humans in 1958, is associated with the accumulation of surfactant lipids and proteins in the airspaces that impair gas exchange, causing dyspnea, fatigue, and exercise intolerance (9). A milk-colored bronchoalveolar lavage (BAL) fluid and foamy macrophages are observed. Although accumulation of surfactant phospholipids is a common finding, cholesterol crystals are also sometimes present upon cytological examination (10). Studies in granulocyte/macrophage colony-stimulating factor (GM-CSF) knockout mice have revealed a critical role for GM-CSF in lung homeostasis (reviewed in Ref. 11). Human idiopathic PAP has come to be recognized as an autoimmune condition in which neutralizing antibodies to GM-CSF limit the availability of biologically active GM-CSF. Indeed the presence of autoantibodies to GM-CSF is considered to be diagnostic of PAP (12).

It has been reported that the addition of CSFs to peripheral blood monocytes in vitro can induce the expression of an alveolar macrophage phenotype, as defined by a variety of functional parameters, including surfactant catabolism and phagocytosis (13). Transcriptional analysis of more than 50,000 genes using a Serial Analysis of Gene Expression (SAGE) approach identified a set of genes highly regulated after in vitro differentiation by GM-CSF (14). Interestingly, several genes involved in lipid homeostasis were highly induced compared with control cells, including apolipoprotein E (>150-fold increase) and CYP27A1 (30-fold increase), two genes involved in reverse cholesterol transport. Similar, although less pronounced, increases were observed after differentiation in the presence of M-CSF (100- and 6-fold, respectively).

These findings prompted us to investigate if the accumulation of cholesterol in PAP alveolar macrophages is attributable to impaired induction of CYP27A1 and a loss of this cholesterol-removal pathway.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Materials
All organic solvents used were of gas chromatography or high performance liquid chromatography grade. Internal standards for gas chromatography-mass spectrometry were as previously described (15).

Patients
This study was approved by the Cleveland Clinic Institutional Review Board, and informed consent was obtained from all subjects. The diagnosis of PAP was established by open lung or transbronchial biopsy. The characteristics of the patients with PAP were as follows: age, 42 ± 7 years (mean ± SD); male-to-female ratio, 10:4. None of the subjects was on medication at the times the samples were obtained. None of the PAP patients gave a history suggestive of underlying liver disease. On examination, there were no stigmata of chronic liver disease (i.e., no hepatomegaly). Baseline liver function studies were available for nine PAP patients, seven of which were completely normal, with two patients displaying mild increases of transaminases (i.e., <2-fold increase above normal). None of the patients had increased bilirubin. The PAP in these patients was felt to be idiopathic in all cases based on the exclusion of known secondary causes of PAP. Healthy volunteers (n = 13) were identified by local advertising and through the employee pool.

BAL fluid and serum
BAL was performed as previously described (16). Fluid was separated from cells, divided into aliquots, and stored at –80°C until assayed. Serum samples were obtained from all patients with PAP and control subjects at the time of BAL. Briefly, peripheral blood was collected in serum separator tubes, centrifuged, divided into aliquots, and stored at –80°C until assayed.

Determination of albumin levels
Albumin levels were estimated by means of a routine enzymatic colorimetric assay using a Roche/Hitachi modular analyzer (17).

Determination of levels of cholestenoic acid and 27-OH
27-OH levels were determined using sensitive isotope dilution mass spectrometry as previously described (15, 18), with the exception that 50 ng of internal standard ([2H6]27-OH) was used. The use of a smaller amount of internal standard was necessitated by the limited amount of sample material available for analysis.

Cholestenoic acid was determined essentially as previously described. Briefly, 200 ng of the internal standard nor -cholestenoic acid was added to an aliquot of serum, and the volume was adjusted to 1 ml using physiological saline. After the addition of 6 ml of chloroform-methanol (2:1, v/v), the sample was vigorously mixed and centrifuged at 1,600 g for 5 min. The organic phase was transferred to a new tube, dried under a gentle stream of nitrogen, and redissolved in 0.5 ml of chloroform. This extract was then applied to an BondElut® NH2 column (Varian, Harbor City, CA), which had been previously conditioned with 4 ml of n-hexane. Neutral and acidic lipids were eluted sequentially with 4 ml of chloroform-isopropanol (2:1, v/v) and acetic acid-diethyl ether (1:49, v/v), respectively. Samples were dried under nitrogen, methylated using diazomethane, and finally trimethylsilated with a mixture of pyridine-hexamethyldisilazane-trichloromethylsilane (3:2:1, v/v/v) as previously described (18). Samples were analyzed by GC-MS according to previously published conditions.

Quantification of mRNA levels by real-time PCR
Levels of mRNA of CYP27A1 and ACAT-1 were determined with real-time quantitative PCR. Alveolar macrophage cDNA from healthy controls and PAP patients was synthesized according to standard procedures. Analysis of the expression levels was performed using single-plex real-time PCR analysis and FAM-labeled probe mixtures on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). Probe mixtures, from Applied Biosystem's Assay-on-demandTM service, were as follows: CYP27A1 (Assay ID: Hs00168003_ml) and ACAT-1 (Assay ID: Hs00162077_ml). Cyclophilin A (Assay ID: Hs99999904_ml) was used as an internal standard. All samples were analyzed in triplicate, and data were analyzed by the comparative threshold cycle ({Delta}{Delta}CT) method as described by the manufacturer (19). Results from PAP patients are expressed as means ± range relative to healthy controls, which were set at a reference value of 1.

Ethical aspects
All experiments were reviewed and approved by The Cleveland Clinic Foundation Institutional Review Board and by the Huddinge University Hospital Ethics Committee.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
CYP27A1 and ACAT-1 mRNA expression is unchanged in PAP alveolar macrophages
To determine if increased cholestenoic acid in the circulation was attributable to altered expression of CYP27A1, mRNA expression levels were quantified by real-time PCR. The mRNA expression of CYP27A1 in alveolar macrophages of PAP patients was not significantly different compared with that of healthy controls (mean and range relative to controls: 0.61, 0.21–1.8; n = 4). To evaluate the possibility of altered cholesterol esterification in PAP alveolar macrophages, expression levels of ACAT-1 were determined. ACAT-1 expression was not significantly different from that of healthy controls (mean and range relative to controls: 0.72, 0.31–1.7; n = 4).

Relation between BAL M-CSF level, cholesterol, and sterol metabolites
M-CSF is a pleiotropic cytokine that shares many activities with GM-CSF, although both cytokines lead to the development of distinct subsets of mature cells (20). As it has previously been reported that PAP patients have vastly increased levels of M-CSF (12), it was considered prudent to investigate possible relationships between M-CSF and pulmonary sterols. No correlation was observed between the BAL levels of M-CSF and the corresponding levels of cholestenoic acid or 27-OH. This is in agreement with our previous reports that demonstrated that M-CSF is not a critical factor for the induction of cholesterol-removal capacity during the differentiation of human monocytes to macrophages (21). There was, however, a significant correlation between the levels of M-CSF and cholesterol in the BAL of PAP patients (r 2 = 0.72) but not in healthy controls (r 2 = 0.11) (Fig. 1) .



View larger version (13K):
[in this window]
[in a new window]
  		Fig. 1. Correlation between bronchoalveolar lavage (BAL) macrophage colony-stimulating factor (M-CSF) and cholesterol in pulmonary alveolar proteinosis (PAP) patients (n = 7; r 2 = 0.72). No significant correlation was observed for healthy controls (HC; n = 8; r 2 = 0.1).

 
Cholesterol is increased in BAL fluid of PAP patients
Cholesterol is an essential component of the pulmonary surfactant, and cholesterol crystals are occasionally observed in cytological examinations of BAL fluid from PAP patients (9). In accordance with earlier findings (10, 22), total cholesterol levels were found to be significantly increased (P = 0.011) in BAL fluid from PAP patients (6.9 ± 1.14 mg/ml; n = 14) compared with healthy controls (3.3 ± 0.64 mg/ml; n = 13) (Fig. 2) . There was no significant difference in serum cholesterol levels between the controls and PAP patients (2.7 ± 0.1 mM and 2.9 ± 0.1 mM, respectively).



View larger version (10K):
[in this window]
[in a new window]
  		Fig. 2. Cholesterol levels in BAL fluid of healthy controls (HC; n = 13) and PAP patients (n = 14). Mean cholesterol levels were 3.3 ± 0.64 mg/ml and 6.92 ± 1.14 mg/ml, respectively. Results are shown as mean ± SEM.

 
Cholestenoic acid and 27-OH are increased in the BAL fluid and serum of patients with PAP
The conversion of cholesterol into more polar metabolites (such as 27-OH and cholestenoic acid) is believed to be a mechanism by which extrahepatic cells eliminate cholesterol (1). To estimate the contribution of this process to pulmonary cholesterol accumulation in PAP, the concentrations of these sterols were measured in matching BAL fluid and serum of patients with PAP.

In the BAL fluid of PAP patients, the absolute levels of 27-OH and cholestenoic acid were significantly increased (P = 0.001 and P = 0.012, respectively) compared with those of healthy controls (Fig. 3) . Absolute levels of cholestenoic acid and 27-OH were significantly increased (P = 0.027 and P = 0.014, respectively) in the serum of PAP patients compared with those of controls (Fig. 4A, C) . Predictably, the levels of total 27-oxygenated sterols in the serum were significantly increased in the PAP group (P = 0.015).




View larger version (21K):
[in this window]
[in a new window]
  		Fig. 3. Levels of 27-oxygenated cholesterol metabolites in BAL fluid of PAP patients and healthy controls (HC). A: Concentration of 27-hydroxycholesterol (27-OH) in BAL fluid. B: Concentration of cholestenoic acid in BAL fluid. Results are shown as mean ± SEM.

 





View larger version (51K):
[in this window]
[in a new window]
  		Fig. 4. Levels of 27-oxygenated cholesterol metabolites in serum of PAP patients and healthy controls (HC). A: Absolute level of 27-OH in serum. B: Cholesterol-related concentration of 27-OH in serum. C: Absolute concentration of cholestenoic acid in serum. D: Albumin-related cholestenoic acid concentration in serum. Results are shown as mean ± SEM.

 
As they are both transported in lipoproteins (15), the serum levels of 27-OH and cholesterol are highly correlated in a normal population. Accordingly, this ratio is used when comparing different groups. As Fig. 4B shows, there was a highly significant increase in the ratio of 27-OH to cholesterol (P = 0.017).

In contrast, cholestenoic acid is mainly transported in the lipoprotein-free fraction of plasma (15), and albumin levels are believed to reflect the bulk transport capacity of the circulation for cholestenoic acid. Albumin levels were measured in conjunction with the cholestenoic acid measurements. There was no significant difference in the albumin levels of the healthy controls and the PAP patients (41.8 ± 1 g/l and 39.3 ± 1.4 g/l, respectively). However, the albumin-related levels of cholestenoic acid were significantly increased (P = 0.003) in serum of PAP patients (Fig. 4D). Under ostensibly normal conditions, there is a close correlation between albumin and cholestenoic acid levels in the circulation (A. Babiker, personal communication). In agreement with these findings, a similar correlation was observed in the healthy controls (r 2 = 0.69, P = 0.012) but not in the PAP patients, in whom there was an uncoupling of the relationship between serum albumin and cholestenoic acid (Fig. 5) .



View larger version (14K):
[in this window]
[in a new window]
  		Fig. 5. Correlation between serum albumin and cholestenoic acid in healthy controls (n = 13) and PAP patients (n = 14). Only the correlation line for the healthy controls is shown (r 2 for PAP group = 0.06).

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The previous demonstrations that CYP27A1 expression is to some extent regulated by GM-CSF, and the predominantly pulmonary origin of circulating cholestenoic acid, led us to hypothesize that PAP patients with high-titer neutralizing antibodies to GM-CSF may have decreased levels of cholestenoic acid. In contrast to these expectations, we observed a significant increase in the levels of 27-oxygenated metabolites in the serum and BAL fluid of PAP patients. According to the present data, this difference does not appear to be the result of altered expression of CYP27A1 in the alveolar macrophages of PAP patients but rather is attributable to an increase in substrate supply.

The absence of a difference in ACAT-1 expression is consistent with previous data that demonstrated that ACAT-1 activity is mainly regulated by substrate supply, at least in some cell types (23). The expression levels observed in the present work thus likely reflect the loading of the macrophages with cholesterol. Because of limitations in the sample material, it was not possible to evaluate the expression of CYP27A1 and ACAT-1 at the protein level.

However, as CYP27A1 can multiply hydroxylate cholesterol at the C-27 position, the total production of 27-OH and cholestenoic acid, as well as the ratio between them, is dependent on the CYP27A1 expression level. It has previously been shown that as the level of CYP27A1 increases, so too does the amount of cholestenoic acid produced relative to 27-OH (3). Thus, increased enzyme expression would be expected to result in a correlation between the total 27-oxygenated products and the cholestenoic acid/27-OH ratio. There was no significant correlation between these factors in the serum of either the PAP patients or healthy controls or in the BAL of the healthy controls (results not shown). In the BAL of PAP patients, a significant correlation was observed, in contrast to the mRNA data. It should be emphasized that the concentration of sterols present in BAL is determined by the contribution of the entire alveolar cell population, not just the alveolar macrophages. Based on the present data, it cannot be excluded that there may be some alteration in CYP27A1 protein levels, particularly in light of the large range in the mRNA levels.

One possible explanation for the variance in mRNA levels is that the BAL of PAP patients contains altered levels of several cytokines, including monocyte chemoattractant protein (MCP)-1, interleukin-8, interleukin-10, and M-CSF, the levels of which may vary with the severity of the disease. However, with the exception of M-CSF, the influence of these cytokines on the regulation of CYP27A1 mRNA expression has not been evaluated. According to experiments in this laboratory, supraphysiological levels (50 ng/ml) of M-CSF do not appear to affect the mRNA expression of CYP27A1, or the production of 27-oxygenated products by human monocyte-derived macrophages, compared with untreated cells (21). This is in contrast to a previous work (14) that demonstrated an induction of CYP27A1 after M-CSF treatment. An important difference in these experiments is that in those demonstrating induction, cells were differentiated in a serum-containing medium, suggesting that other competence factors may be required for the induction of CYP27A1 expression.

To exclude the possibility that abnormal hepatic metabolism of circulating 27-OH was involved in the increased levels, a pool of serum from seven of the PAP patients was analyzed for the presence of bile acids by gas chromatography-mass spectrometry. Normal levels of chenodeoxycholic acid, deoxycholic acid, and cholic acid were present, in addition to trace amounts of ursodeoxycholic acid. No unusual bile acids or bile acid precursors (e.g., di- and trihydroxycoprostanoic acids) were observed in this material.

Based on the available data, the most likely explanation for the increase in the concentration of the 27-oxygenated metabolites observed in the present work is an increase in substrate availability, which is rate-limiting for the formation of 27-OH.

The entry of cholesterol into the mitochondrial lumen is generally accepted as the rate-limiting step in the production of 27-OH by CYP27A1 (24). In steroidogenic tissues, the steroidogenic acute regulatory (StAR) protein is a critical component of the mitochondrial cholesterol import mechanism (25). However, as StAR is not expressed outside of these tissues, it is unclear what mechanisms are responsible for the delivery of cholesterol to CYP27A1 in nonsteroidogenic tissues. The recent elucidation of a StAR protein family in which all members possess a START domain raises the possibility that a member of this protein family may be responsible for shuttling cholesterol to the mitochondrial lumen in nonsteroidogenic cells (26). Recently, a transgenic mouse model with a targeted deletion of the START domain of StARD3 was developed (27). However, no significant cholesterol accumulation was observed in homozygous animals, indicating that the presence of the StARD3 START domain is not essential for cholesterol delivery to mitochondria. To date, the role of other putative "cholesterol-delivery" factors has not been evaluated in alveolar macrophages.

The reason why the lung has a high capacity to produce cholestenoic acid is unclear. As the lung derives most of its cholesterol from circulating lipoproteins, feedback regulation of lipoprotein receptors after the accumulation of cholesterol would be expected to downregulate the lipoprotein receptors and reduce the amount of cholesterol entering the lung. Moreover, it has been demonstrated that HDL can interact with both type II pneumocytes (28) and alveolar macrophages, indicating that both of these cell types have the capacity to participate in lipoprotein-mediated reverse cholesterol transport.

As alveolar surfactant is the first target for air-borne oxidants, the possibility may be considered that, as a result of its broad substrate specificity (29), CYP27A1 may be responsible for detoxifying oxygenated sterols that are unable to participate in the surfactant-recycling pathways. In this connection, it is notable that a recent study described the formation of several biologically active sterols after exposure to ozone (30), indicating that in addition to contributing to the elimination of nonrecyclable sterols, CYP27A1 may also be involved in the deactivation of cytotoxic sterols. A final hint of the possible role of CYP27A1 in the lung is the recent demonstration of an oxysterol-regulated ABCA1-mediated basolateral surfactant efflux pathway (31). As 27-OH has been shown, at least under some in vitro conditions (32), to be an activator of the liver X receptor family of nuclear receptors, CYP27A1 may be involved in the regulation of this proposed efflux pathway.

As surfactant represents a significant pool of cholesterol in the lung, there may be a coupling between the catabolism of surfactant lipids by alveolar macrophages and the production of cholestenoic acid. In preliminary experiments, sterol 27-hydroxylase activity and CYP27A1 immunoreactivity were detected in purified lamellar bodies from human lung (S. Meaney, unpublished observations). This is in agreement with previous electron microscopy results that demonstrated immunopositive material in the lamellar bodies of tissue from healthy lung (33).

According to published data, an average pair of human lungs contains 2–3 g of cholesterol, of which 40–60 mg is believed to be associated with the surfactant. As the conversion of cholesterol into cholestenoic acid results in the elimination of ~15 mg of cholesterol from the lung each day, we hypothesize that the elimination of cholesterol as cholestenoic acid may be important in the processing of surfactant cholesterol by alveolar macrophages. Studies are in progress to test the relationship between surfactant cholesterol and serum cholestenoic acid.


   ACKNOWLEDGMENTS
 
This work was supported by Stiftelsen Lars Hiertas Minne, the Swedish Medical Research Council, the Swedish Heart-Lung Foundation, and National Institutes of Health Grant HL-67676 (M.J.T.).

Manuscript received August 9, 2004 and in revised form September 16, 2004.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
  1. Lund, E., O. Andersson, J. Zhang, A. Babiker, G. Ahlborg, U. Diczfalusy, K. Einarsson, J. Sjövall, and I. Björkhem. 1996. Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arterioscler. Thromb. Vasc. Biol. 16: 208–212.[Abstract/Free Full Text]

  2. Pikuleva, I. A., A. Babiker, M. R. Waterman, and I. Björkhem. 1998. Activities of recombinant human cytochrome P450c27 (CYP27) which produce intermediates of alternative bile acid biosynthetic pathways. J. Biol. Chem. 273: 18153–18160.[Abstract/Free Full Text]

  3. Babiker, A., O. Andersson, E. Lund, R. J. Xiu, S. Deeb, A. Reshef, E. Leitersdorf, U. Diczfalusy, and I. Björkhem. 1997. Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J. Biol. Chem. 272: 26253–26261.[Abstract/Free Full Text]

  4. Babiker, A., O. Andersson, D. Lindblom, J. van der Linden, B. Wiklund, D. Lütjohann, U. Diczfalusy, and I. Björkhem. 1999. Elimination of cholesterol as cholestenoic acid in human lung by sterol 27-hydroxylase: evidence that most of this steroid in the circulation is of pulmonary origin. J. Lipid Res. 40: 1417–1425.[Abstract/Free Full Text]

  5. Veldhuizen, R., K. Nag, S. Orgeig, and F. Possmayer. 1998. The role of lipids in pulmonary surfactant. Biochim. Biophys. Acta. 1408: 90–108.[Medline]

  6. Turley, S. D., J. M. Andersen, and J. M. Dietschy. 1981. Rates of sterol synthesis and uptake in the major organs of the rat in vivo. J. Lipid Res. 22: 551–569.[Abstract]

  7. Voyno-Yasenetskaya, T. A., L. G. Dobbs, S. K. Erickson, and R. L. Hamilton. 1993. Low density lipoprotein- and high density lipoprotein-mediated signal transduction and exocytosis in alveolar type II cells. Proc. Natl. Acad. Sci. USA. 90: 4256–4260.[Abstract/Free Full Text]

  8. Batenburg, J. J., and H. P. Haagsman. 1998. The lipids of pulmonary surfactant: dynamics and interactions with proteins. Prog. Lipid Res. 37: 235–276.[CrossRef][Medline]

  9. Trapnell, B. C., J. A. Whitsett, and K. Nakata. 2003. Pulmonary alveolar proteinosis. N. Engl. J. Med. 349: 2527–2539.[Free Full Text]

  10. Sosolik, R. C., R. R. Gammon, C. J. Julius, and L. W. Ayers. 1998. Pulmonary alveolar proteinosis. A report of two cases with diagnostic features in bronchoalveolar lavage specimens. Acta Cytol. 42: 377–383.[Medline]

  11. Trapnell, B. C., and J. A. Whitsett. 2002. GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu. Rev. Physiol. 64: 775–802.[CrossRef][Medline]

  12. Bonfield, T. L., D. Russell, S. Burgess, A. Malur, M. S. Kavuru, and M. J. Thomassen. 2002. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am. J. Respir. Cell Mol. Biol. 27: 481–486.[Abstract/Free Full Text]

  13. Shibata, Y., P. Y. Berclaz, Z. C. Chroneos, M. Yoshida, J. A. Whitsett, and B. C. Trapnell. 2001. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. 15: 557–567.[CrossRef][Medline]

  14. Hashimoto, S., T. Suzuki, H. Y. Dong, N. Yamazaki, and K. Matsushima. 1999. Serial analysis of gene expression in human monocytes and macrophages. Blood. 94: 837–844.[Abstract/Free Full Text]

  15. Babiker, A., and U. Diczfalusy. 1998. Transport of side-chain oxidized oxysterols in the human circulation. Biochim. Biophys. Acta. 1392: 333–339.[Medline]

  16. Thomassen, M. J., T. Yi, B. Raychaudhuri, A. Malur, and M. S. Kavuru. 2000. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin. Immunol. 95: 85–92.[CrossRef][Medline]

  17. Doumas, B., and H. Biggs. 1972. Standard Methods of Clinical Chemistry. Vol. 7. G. Cooper, editor. Academic Press, New York. 175–188.

  18. Dzeletovic, S., O. Breuer, E. Lund, and U. Diczfalusy. 1995. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal. Biochem. 225: 73–80.[CrossRef][Medline]

  19. Applied Biosystems. 2001. Relative Quantification of Gene Expression. User Bulletin 2. Applied Biosystems, Foster City, CA. 1–36.

  20. Barreda, D. R., P. C. Hanington, and M. Belosevic. 2004. Regulation of myeloid development and function by colony stimulating factors. Dev. Comp. Immunol. 28: 509–554.[CrossRef][Medline]

  21. Hansson, M., E. Ellis, M. C. Hunt, G. Schmitz, and A. Babiker. 2003. Marked induction of sterol 27-hydroxylase activity and mRNA levels during differentiation of human cultured monocytes into macrophages. Biochim. Biophys. Acta. 1593: 283–289.[Medline]

  22. Doyle, I. R., K. G. Davidson, H. A. Barr, T. E. Nicholas, K. Payne, and J. Pfitzner. 1998. Quantity and structure of surfactant proteins vary among patients with alveolar proteinosis. Am. J. Respir. Crit. Care Med. 157: 658–664.

  23. Matsuda, H., H. Hakamata, A. Miyazaki, M. Sakai, C. C. Chang, T. Y. Chang, S. Kobori, M. Shichiri, and S. Horiuchi. 1996. Activation of acyl-coenzyme A:cholesterol acyltransferase activity by cholesterol is not due to altered mRNA levels in HepG2 cells. Biochim. Biophys. Acta. 1301: 76–84.[Medline]

  24. Pandak, W. M., S. Ren, D. Marques, E. Hall, K. Redford, D. Mallonee, P. Bohdan, D. Heuman, G. Gil, and P. Hylemon. 2002. Transport of cholesterol into mitochondria is rate-limiting for bile acid synthesis via the alternative pathway in primary rat hepatocytes. J. Biol. Chem. 277: 48158–48164.[Abstract/Free Full Text]

  25. Hauet, T., J. Liu, H. Li, M. Gazouli, M. Culty, and V. Papadopoulos. 2002. PBR, StAR, and PKA: partners in cholesterol transport in steroidogenic cells. Endocr. Res. 28: 395–401.[CrossRef][Medline]

  26. Soccio, R. E., and J. L. Breslow. 2003. StAR-related lipid transfer (START) proteins: mediators of intracellular lipid metabolism. J. Biol. Chem. 278: 22183–22186.[Free Full Text]

  27. Kishida, T., I. Kostetskii, Z. Zhang, F. Martinez, P. Liu, S. U. Walkley, N. K. Dwyer, E. J. Blanchette-Mackie, G. L. Radice, and J. F. Strauss 3rd. 2004. Targeted mutation of the MLN64 START domain causes only modest alterations in cellular sterol metabolism. J. Biol. Chem. 279: 19276–19285.[Abstract/Free Full Text]

  28. Guthmann, F., B. Harrach-Ruprecht, A. C. Looman, P. A. Stevens, H. Robenek, and B. Rustow. 1997. Interaction of lipoproteins with type II pneumocytes in vitro: morphological studies, uptake kinetics and secretion rate of cholesterol. Eur. J. Cell Biol. 74: 197–207.[Medline]

  29. Norlin, M., S. von Bahr, I. Björkhem, and K. Wikvall. 2003. On the substrate specificity of human CYP27A1: implications for bile acid and cholestanol formation. J. Lipid Res. 44: 1515–1522.[Abstract/Free Full Text]

  30. Pulfer, M. K., and R. C. Murphy. 2004. Formation of biologically active oxysterols during ozonolysis of cholesterol present in lung surfactant. J. Biol. Chem. 279: 26331–26338.[Abstract/Free Full Text]

  31. Agassandian, M., S. N. Mathur, J. Zhou, F. J. Field, and R. K. Mallampalli. 2004. Oxysterols trigger ABCA1-mediated basolateral surfactant efflux. Am. J. Respir. Cell Mol. Biol. 31: 227–233.[Abstract/Free Full Text]

  32. Fu, X., J. G. Menke, Y. Chen, G. Zhou, K. L. MacNaul, S. D. Wright, C. P. Sparrow, and E. G. Lund. 2001. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276: 38378–38387.[Abstract/Free Full Text]

  33. Babiker, A. 1998. Studies on a Novel Oxidative Mechanism for Elimination of Extrahepatic Cellular Cholesterol. PhD Dissertation. Stockholm, Karolinska Institute.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
M. J. Thomassen, B. P. Barna, A. G. Malur, T. L. Bonfield, C. F. Farver, A. Malur, H. Dalrymple, M. S. Kavuru, and M. Febbraio
ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis
J. Lipid Res., December 1, 2007; 48(12): 2762 - 2768.
[Abstract] [Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
O C Ioachimescu and M S Kavuru
Pulmonary alveolar proteinosis
Chronic Respiratory Disease, July 1, 2006; 3(3): 149 - 159.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M400302-JLR200v1
45/12/2354    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meaney, S.
Right arrow Articles by Thomassen, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meaney, S.
Right arrow Articles by Thomassen, M. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Advertisement
spacer
Advertisement
Advertisement